Sanofi SNY

Sanofi is actively transforming into an R&D-driven, AI-powered biopharma company. This strategic shift was supported by the completion of the Opella divestment, which generated EUR 10.4 billion. These proceeds were reinvested into value-creating business development and M&A opportunities, including Blueprint, Vicebio, Dren Bio DR-0201, and Vigil. The company also completed its EUR 5 billion share buyback program in 2025 and plans a EUR 1 billion buyback for 2026, demonstrating a commitment to shareholder returns while investing in long-term growth.

Dupixent remains a key growth driver, achieving EUR 15.7 billion in annual sales for FY25, with a strong 32% growth in Q4 to EUR 4.2 billion. This growth was fueled by continued penetration across anchor indications and successful expansion into new areas like COPD, CSU, and BP. Patient adoption increased by over 30% in the past year, solidifying Dupixent's position as the #1 prescribed biologic across multiple specialist categories. The U.S. regulatory acceptance for the allergic fungal rhinosinusitis (AFRS) indication further expands its potential market reach.

Sanofi's newly launched medicines and vaccines demonstrated significant success, contributing EUR 5.7 billion in sales for 2025, representing 34% growth. Beyfortus, for RSV protection, delivered EUR 1.8 billion in full-year sales, exceeding modest growth expectations and protecting over 11 million babies globally. ALTUVIIIO achieved blockbuster status with EUR 1.2 billion in full-year sales, driven by increasing patient adoption. AYVAKIT also performed strongly, reaching $725 million in annual pro forma sales, slightly ahead of expectations.

The vaccines portfolio generated EUR 7.9 billion in full-year sales, maintaining leadership in influenza and RSV. Sanofi is strategically enhancing this segment, particularly for older adults. Key acquisitions include Vicebio, adding a bivalent RSV + human metapneumovirus vaccine candidate, and the proposed acquisition of Dynavax Technologies Corporation, which will bring HEPLISAV-B (adult hepatitis B vaccine) and a shingles vaccine candidate, further diversifying the pipeline in this area.

Sanofi's pipeline delivered 12 Phase III and 15 Phase II readouts in 2025, with 10 new molecules, including three gene therapies, entering Phase I. The company secured 20 regulatory approvals and 22 acceptances, including 9 priority reviews. Notable progress includes positive Phase III results for amlitelimab in atopic dermatitis. However, tolebrutinib did not meet its primary endpoint in the PERSEUS study for PPMS, leading to the discontinuation of its regulatory submission for this indication, reflecting a dynamic capital allocation strategy for the pipeline.

China remains a strategic priority for Sanofi, with significant progress made by its regional team. The company obtained approvals for global medicines such as Cablivi (for acquired TTP) and Qfitlia (for hemophilia). Additionally, China-only medicines like Myqorzo (for obstructive hypertrophic cardiomyopathy) and Redemplo (for familial chylomicronemia syndrome) received approvals, underscoring Sanofi's dedication to bringing innovative treatments to Chinese patients and leveraging local innovation.

Sanofi highlighted its leadership in sustainable healthcare by playing a key role in developing PAS 2090. This is the first industry-wide global standard for measuring and reducing the environmental impact of medicines and vaccines across their life cycle. Published by the British Standards Institution, this harmonized framework aims to enable ecodesign, accurate environmental reporting, and address stakeholder demands for transparency, showcasing collaboration for meaningful progress in patient and planet health.